Sublingual application of liquid nitrendipine does not result in critical hypotension in healthy volunteers under phosphodiesterase-5 inhibition

Clinical Hemorheology and Microcirculation

Volumn 39, Issue 1-4, 2008, Pages 323-328

  Park, J W ^a   Leithauser B ^a   Jung, F ^b  

^a Hoyerswerda Hospital   (Germany)

^b CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

Author keywords

Cardiovascular disease; Erectile dysfunction; Nitrendipine; Phosphodiesterase 5 inhibitors

Indexed keywords

NITRENDIPINE; PHOSPHODIESTERASE V; TADALAFIL;

ADULT; ANGINA PECTORIS; BLOOD PRESSURE MEASUREMENT; CLINICAL TRIAL; COMPARATIVE STUDY; CONFERENCE PAPER; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CORONARY ARTERY DISEASE; DRUG SAFETY; ENZYME INHIBITION; HUMAN; HUMAN EXPERIMENT; HYPOTENSION; MALE; NORMAL HUMAN; RANDOMIZED CONTROLLED TRIAL; SELF MEDICATION; STATISTICAL SIGNIFICANCE; SYSTOLIC BLOOD PRESSURE;

ADMINISTRATION, SUBLINGUAL; ADULT; ANGINA PECTORIS; BLOOD PRESSURE; CARBOLINES; CARDIOVASCULAR DISEASES; CYCLIC NUCLEOTIDE PHOSPHODIESTERASES, TYPE 5; DOSAGE FORMS; DRUG INTERACTIONS; ERECTILE DYSFUNCTION; HUMANS; HYPOTENSION; MALE; NITRENDIPINE; PHOSPHODIESTERASE INHIBITORS;

EID: 47849104732     PISSN: 13860291     EISSN: None     Source Type: Journal    
DOI: 10.3233/CH-2008-1096     Document Type: Conference Paper

References (13)

1. H. Sperling, G. Lümmen, T. Schneider and H. Rübben, Neue Therapieoptionen zur Behandlung der erektilen Dysfunktion, Herz 28 (2003), 314-324.
2. J.T. Emmick, S.R. Stuewe and M. Mitchell, Overview of the cardiovascular effects of tadalafil, Eur. Heart 4 (2002), H32-H47.
3. D.J. Webb, G.J. Muirhead, M. Wulff et al., Sildenafil citrate potentiates the hypotensive effects of nitric oxide donor drugs in male patients with stable angina, J. Am. Coll. Cardiol. 36 (2000), 25-31.
4. D.J. Webb, S. Freestone, M.J. Allen et al., Sildenafil citrate and blood pressure lowering drugs: results of drug interaction studies with an organic citrate and calcium antagonist, Am. J. Cardiol. 83 (1999), 21C-88C.
5. R.A. Kloner, A.M. Hurter, J.T. Emmick et al., Time course of the interaction between tadalafil and nitrates, J. Am. Coll. Cardiol. 42 (2003), 1855-1860.
6. M.D. Cheitlin, A.M. Hutter, R.G. Brindis et al., ACC/AHA expert consensus document. Use of sildenafil (Viagra) in patients with cardiovascular disease, J. Am. Coll. Cardiol. 33 (1999), 273-282.
7. L.A. Levine, Erectile dysfunction: causes, diagnosis and treatment, Compr. Ther. 15 (1989), 54-58.
8. G. Jackson, J. Betteridge, J. Dean et al., A systematic approach to erectile dysfunction in the cardiovascular patient: A consensus statement, Int. J. Clin. Pract. 53 (1999), 445-451.
9. E. Van Bavel, E.N. Bakker, A. Pistea, O. Sorop and J.A. Spaan, Mechanics of microvascular remodeling, Clin. Hemorheol. Microcirc. 34(1/2) (2006), 35-41.
10. R. Lo Presti, T. D'Amico, M. Montana, B. Canino, G. Amodeo, M.G. Tozzi Ciancarelli and G. Caimi, Evaluation of oxidative status in coronary heart disease at baseline and during exercise test, Clin. Hemorheol. Microcirc. 37(4) (2007), 339-345.
11. D. Patterson, R. Kloner, M. Effron et al., The effect of tadalafil on the time to exercise-induced myocardial ischaemia in subjects with coronary artery disease, Br. J. Clin. Pharmacol. 60 (2005), 459-468.
12. R.A. Kloner, Cardiovascular effects of the 3 phosphodiesterase-5 inhibitors approved for the treatment of erectile dysfunction, Circulation 110 (2004), 3149-3155.
13. D.D. Stromberg and C.A. Wiederhielm, Functional aspects of the microcirculation, in: The Microcirculation in Clinical Medicine, R. Wells, ed., Academic Press, New York, 1973, p. 33.